¹Ý¼®½áÄ¡(ÁÖ)

[´ë±â¾÷ ¹ÙÀÌ¿ÀÆÀÀå]´ëÀü Áß°ß¹ÙÀÌ¿À»óÀå»ç

¸ðÁýºÎ¹® ¹× ÀÚ°Ý¿ä°Ç

¸ðÁýºÎ¹® ´ã´ç¾÷¹« ÀÚ°Ý¿ä°Ç Àοø
¸é¿ªÇÐ ¹ÙÀÌ¿ÀÆÀÀå

[´ã´ç¾÷¹«]

Ph.D. degree in pharmacology, biology, molecular biology, biochemistry, or related field

10+ years (at least 5+ years in Immuno-oncology, cancer biology, or antibody therapeutics) of experience in a drug discovery setting (biotech or large pharma) or relevant industry experience in a biopharmaceutical setting with extensive experience from target validation to IND-enabling studies

Demonstrated application of expertise to drug discovery in multiple therapeutic areas, including immuno-oncology

Deep understanding of preclinical PK/PD/efficacy relationships and their translation to the clinic

Strong leadership, interpersonal and communication skills with an enthusiasm for participating in a fast-paced environment characterized by rigorous science and innovative thinking

A team player and mentor, who listens effectively and invites response and discussion. A collaborator who communicates in an open, clear, complete, timely and consistent manner

2) ÀÚ°Ý¿ä°Ç

- Àü°ø : ¾à¸®ÇÐ, »ý¹°ÇÐ, ºÐÀÚ»ý¹°ÇÐ, »ýÈ­ÇÐ ¶Ç´Â °ü·Ã Çаú

- Çз : ¹Ú»ç

    

3) ÇʼöÁ¶°Ç

   - 10³â ÀÌ»ó (¸é¿ªÇ×¾ÏÇÐ, ¾Ï»ö¹°ÇÐ ¶Ç´Â Ç×üġ·áÇÐ ºÐ¾ß¿¡¼­ ÃÖ¼Ò 5³â ÀÌ»ó) ¾à¹° ¹ß°ß ȯ°æ(¹ÙÀÌ¿ÀÅØ ¶Ç´Â ´ëÇü Á¦¾à»ç) ¿¡¼­ÀÇ °æÇè (10³â ÀÌ»ó »ê¾÷ü¿¡¼­ ½Å¾à°³¹ß °æÇè)

   - µð½ºÄ¿¹ö¸® ´Ü°èºÎÅÍ IND ±îÁö ±¤¹üÀ§ÇÑ °æÇèÀ» °¡Áø °ü·Ã ¾÷°è °æÇè


0 ¸í

±Ù¹«Á¶°Ç

  • °í¿ëÇüÅÂ: Á¤±ÔÁ÷
  • ±Þ¿©Á¶°Ç: ¿¬ºÀ ÇùÀÇ ÈÄ °áÁ¤

ÀüÇü´Ü°è ¹× Á¦Ãâ¼­·ù

  • ÀüÇü´Ü°è: ¼­·ùÀüÇü > ¸éÁ¢ÁøÇà > ÃÖÁ¾½É»ç > ÃÖÁ¾ÇÕ°Ý
  • Ãß°¡ Á¦Ãâ¼­·ù
    À̷¼­, ÀÚ±â¼Ò°³¼­

Á¢¼ö¹æ¹ý

2024-10-03 (¸ñ) 23½Ã59ºÐ±îÁö

  • Á¢¼ö¹æ¹ý: ÀÎÅ©·çÆ® ä¿ë½Ã½ºÅÛ
  • Á¢¼ö¾ç½Ä: ÀÎÅ©·çÆ® À̷¼­

±âŸ À¯ÀÇ»çÇ×

  • ÀÔ»çÁö¿ø¼­ ¹× Á¦Ãâ¼­·ù¿¡ ÇãÀ§»ç½ÇÀÌ ÀÖÀ» °æ¿ì ä¿ëÀÌ Ãë¼ÒµÉ ¼ö ÀÖ½À´Ï´Ù.

00